North American Region is Estimated to Hold a Dominant Stake in the Global Ovarian Cancer Diagnostics Market Share by 2031 End

Market Taxonomy

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

• rising presence of carcinogenic elements in common consumables
• surging exposure to toxic substances in factories & industrial settings
• lack of awareness related to causes, symptoms, and preventive measures for ovarian cancer
• high healthcare costs, deterring ovarian cancer patients from seeking optimum diagnosis

With growing incidence of ovarian cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for ovarian cancer.

As ovarian cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of ovarian cancer.

Need for Premeditated Ovarian Cancer Patient Compliance

Ovarian cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family.

Companies manufacturing medical instruments and devices for diagnosis of ovarian cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.

The global market for ovarian cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings.

Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of ovarian cancer patients.

Key players in the global ovarian cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on ovarian cancer patients.

Such cooperative efforts are of paramount importance in the global ovarian cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Ovarian Cancer diagnostics market – Regional Overview & Competitive Backdrop

A comprehensive section on the regional analysis of global ovarian cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global ovarian cancer diagnostics market is studied.

Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for ovarian cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of ovarian cancer diagnosis instruments.

In the report, there is an elaborate section on the competitive landscape of global ovarian cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus.

The scalability employed in profiling these players includes criteria such as the company’s contribution to global ovarian cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches.

Through this report, companies can also understand the investment standpoint in the global ovarian cancer diagnostics market, which can be further inferred while taking insightful actions.

Key Insights on Global Ovarian Cancer Diagnostics Market:

1. According to the report, diagnosis of epithelial tumors will procure largest share in the global ovarian cancer diagnostics market. With more than 90% share, over US$ 875 Mn revenues are anticipated to be procured by diagnosis of epithelial tumors in the global market.
2. Presence of prominent cancer research societies in the US and Canada is anticipated to boost the contribution of North America towards growth of the global ovarian cancer diagnostics market. In 2017, North America will remain dominant region, procuring nearly US$ 240 Mn in revenues. The ovarian cancer diagnostics market in North America is also pegged to exhibit rapid growth by reflecting an estimated CAGR of 8.7%.
3. Europe’s ovarian cancer diagnostics market is expected to showcase a relatively faster growth in terms of revenues. Robust healthcare infrastructure in a majority of European countries is observed to boost the adoption of ovarian cancer diagnostics in this region. Towards the end of 2022, Europe will record revenues worth a little over US$ 315 Mn in its ovarian cancer diagnostics market.
4. The report anticipates fastest growth in the Asia-Pacific excluding Japan (APEJ) region. Expanding at an estimated 9.5% CAGR, the ovarian cancer diagnostics market in APEJ region will have procured close to US$ 127 Mn by the end of the forecast period.
5. On the basis of test-types, CA 125, HER2 and BRCA are anticipated to be prominent diagnostic tests in the global market. Diagnosis of ovarian cancer through CA125 is expected to account for more than 40% of revenues procured throughout the forecast period. Demand for HER2 testing is also expected to gain traction, reflecting an estimated revenue growth at 9.5% CAGR.
6. The report also observes hospital associated labs as the largest end-users of ovarian cancer diagnostics. In 2017, close to US$ 300 Mn worth of revenues will be procured from hospitals associated labs on ovarian cancer diagnostics.

The report has also profiled leading players in the global ovarian cancer diagnostics market. Companies such as Abbott Laboratories, Thermo Fischer Scientific Inc., Roche Holding AG, Siemens AG, Epigenomics AG, Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics Inc., AstraZeneca plc. and Quest Diagnostics Incorporated are expected to remain active in the growth of global ovarian cancer diagnostics market through 2022.